LYEL - lyell.com Price to Earnings Adjusted for Growth Rate

Corporate company logo of Lyell Immunopharma (LYEL)

Lyell Immunopharma is implementing ESG standards by minimizing laboratory waste and adhering to bioethics. The level of undervaluation based on PEG in the GURU.Markets system visualizes this process, where the parameter value equals 0.00. Lyell Immunopharma is developing a T-cell modification ecosystem to combat tumors, establishing the foundation for a new era of oncology. The company is currently actively developing innovative immunotherapy methods to overcome the barriers of existing approaches.

LYEL: Lyell Immunopharma Inc PEG Multiple 07/04/2022 - 11/17/2026

Metric breakdowns and analytics for Lyell (LYEL)

- market value and analyst target forecast:
Summary company analytics:LYEL Lyell Pharma
Original product of Lyell Immunopharma, Inc.

Lyell Immunopharma (LYEL) utilizes patent-protected T-cell reprogramming technology to create high barriers to entry for competitors under strict FDA oversight. By analyzing the P/E-to-growth trend, an investor compares market valuation with net income dynamics: a value below one signals that the asset is undervalued relative to its expansion, enabling the identification of potentially explosive assets or risks of business model obsolescence.

Competitors of Lyell Immunopharma

ImmunityBio, Inc. (IBRX) - Price to Net Income Growth Ratio|Immunocore Holdings - Price/Earnings to Growth Multiple|Janux Therapeutics, Inc. (JANX) - Price to Earnings Adjusted for Growth Rate|RCUS: Price/Earnings to Growth Multiple|Growth-Adjusted Payback Ratio ZYME (Zymeworks)|TNGX: PEG Multiple|IOVA - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Ratio immatics.com|Price/Earnings to Growth Multiple xencor.com (XNCR)|Price/Earnings to Growth Ratio Compass Therapeutics Inc (CMPX)|Price/Earnings to Growth Multiple Replimune Corp REPL|Innate Pharma SA - Price/Earnings to Growth Multiple|PEG Multiple Pyxis Oncology, Inc. PYXS|CGEN - Price/Earnings to Growth Ratio|IOBT (iobiotech.com) - Growth-Adjusted P/E Ratio|Sutro Biopharma, Inc (STRO) - Price/Earnings to Growth Ratio|Price to Earnings Adjusted for Growth Rate MiNK (INKT)|Price/Earnings to Growth Multiple HOWL|IMMX - Price to Net Income Growth Ratio|Price/Earnings to Growth Multiple ALXO (ALX Oncology Holdings)|CUE (Cue Biopharma) - Growth-Adjusted Payback Ratio|PEG Multiple PDSB (PDS Biotechnology)|Growth-Adjusted Payback Ratio SONN|MAIABiotech.com - PEG Multiple|Price to Earnings Adjusted for Growth Rate Liminatus|Lava Tx (LVTX) - Price/Earnings to Growth Ratio|NextCure, Inc. - Growth-Adjusted Payback Ratio|LPTX (Leap Tx) - PEG Multiple|PEG Multiple intensitytherapeutics.com|Price/Earnings to Growth Ratio senseibio.com (SNSE)|TOVX: Market Cap to Earnings and Growth Ratio|Gritstone bio - Price/Earnings to Growth Multiple|Growth-Adjusted Market Cap to Net Income kinetabio.com (KA)|NEXI - Price/Earnings to Growth Ratio|Turnstone Biologics Corp - Company Value to Earnings Growth Ratio|VCNX: PEG Multiple|Harpoon Therapeutics Corp (HARP) - PEG Multiple